WFRF:(Dorlo Thomas P. C. PhD 1983 )
Search: WFRF:(Dorlo Thomas P. C. PhD 1983 ) > Pyronaridine :
- 9 of 23
- Previous record
- Next record
- To hitlist
- Chu, Wan-YuNetherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands. (author)
Pyronaridine : a review of its clinical pharmacology in the treatment of malaria
- Article/chapterEnglish2023
Publisher, publication year, extent ...
- 2023
- Oxford University Press,2023
- electronicrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-512437
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512437URI
- https://doi.org/10.1093/jac/dkad260DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
- Dorlo, Thomas P. C.,PhD,1983-Uppsala universitet,Institutionen för farmaci,Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands(Swepub:uu)thodo249 (author)
- Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.Institutionen för farmaci (creator_code:org_t)
Related titles
- In:Journal of Antimicrobial Chemotherapy: Oxford University Press0305-74531460-2091
Internet link
Find in a library
- Journal of Antimicrobial Chemotherapy (Search for host publication in LIBRIS)
To the university's database
- 9 of 23
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Chu, Wan-Yu
- Dorlo, Thomas P. ...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Basic Medicine
- and Pharmacology and ...
- Articles in the publication
- Journal of Antim ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
